Open-label, randomized study of lasofoxifene (LAS) vs. fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors - Goetz, M P; Plourde, P; Stover, D G (Ann Oncol, 2022)